Pharma Manufacturing · transition pathways
← all sectorsThe recognised primary transition pathway for pharma manufacturing, plus the upstream sectors pharma manufacturing firms depend on for their own decarbonisation. A consulting firm cutting business travel still needs aviation to decarbonise; a REIT cutting tenant energy still needs the grid to clean up. These are the rate limiters.
SBTi 1.5°C corporate + PSCI + My Green Lab
No pharma-specific SBTi pathway yet. Most majors align via SBTi general 1.5°C corporate targets. PSCI (Pharmaceutical Supply Chain Initiative) drives upstream supplier engagement. My Green Lab certifies lab-energy reduction.
Reference ↗Hover the chart to read off Best / Realistic / Worst values at any year. Click to pin the readout.
Best 0% · Worst 70%
Upstream sectors pharma manufacturing firms rely on. The faster these decarbonise, the faster the firm can hit its own targets — even when it does everything in its control.
Power & electricity
Scope 2Cleanroom HVAC and lab energy are grid-bound. Faster grid decarbonisation cuts the largest direct lever.
Source: IEA WEO 2023 — NZE / APS / STEPS
API + chemicals supply chain
Scope 3 · cat 1Active ingredient synthesis is the largest S3 bucket. Decarbonisation pace of bulk chemicals + fine chemicals manufacturers in Asia caps progress.
HFC refrigerants + propellants
Scope 1 + Scope 3 · cat 4 + cat 11Cold-chain HFC leaks + MDI propellants. Kigali Amendment phase-down sets the schedule.
Aviation
Scope 3 · cat 6 + cat 4Clinical trial sample shipping + global team travel. Cold-chain air freight is doubly energy-intensive.
Source: IATA Fly Net Zero, ICAO LTAG, BAU (~3% pa growth)
Once we have HQ + operations location data per firm in this cohort, we'll overlay Ember grid-carbon-intensity data per country so you can see the geographical decarbonisation tailwind (or headwind) each firm is operating against.
Source: ember-energy.org · Global Electricity Review + per-country grid carbon intensity (gCO2/kWh).